The technical core of the review concerns the kinase-phosphatase equilibrium that governs tau’s phosphorylation state. Tau is a natively unfolded protein that stabilizes microtubules in axons, and its function is tuned by the addition and removal of phosphate groups along its sequence, particularly in the proline-rich region and the microtubule-binding repeat region. When kinases such as glycogen synthase kinase-3 beta, cyclin-dependent kinase 5, microtubule affinity-regulating kinase 4, tau-tubulin kinase 1, tyrosine kinase 2 and cyclin-dependent kinase 3 outpace the phosphatases that oppose them, chiefly protein phosphatase 2A and protein phosphatase 1, hyperphosphorylated tau detaches from microtubules, misfolds and begins to self-assemble. The review emphasizes that this equilibrium is not a simple seesaw: individual kinases act at distinct sites and disease stages, which helps explain why broad kinase inhibition has proven difficult to translate into safe, effective therapies.

Equally important is the emerging picture of cross-talk among post-translational modifications. Phosphorylation does not act alone. The review details how O-GlcNAcylation, acetylation, ubiquitination, methylation, glycation and truncation by enzymes such as asparagine endopeptidase compete for overlapping residues and reshape tau’s conformational landscape. O-GlcNAcylation at serine and threonine residues, for instance, can sterically block phosphorylation at neighboring sites and appears protective in several models, suggesting that enhancing this sugar modification could be a viable strategy. Conversely, truncation of tau can expose aggregation-prone segments and accelerate the transition from soluble tau assemblies into paired helical filaments and straight filaments, the structural components of neurofibrillary tangles that cryo-electron microscopy has now resolved to near-atomic precision in patient brain tissue.

The review also highlights two systemic factors that have rarely been integrated into tau-centric models: nuclear envelope damage and iron metabolism. Hyperphosphorylated tau compromises the nuclear envelope and disrupts nuclear pore complexes, and interactions with the lamin B receptor contribute to DNA damage and transcriptional dysregulation in vulnerable neurons. Meanwhile, disturbed iron homeostasis pushes tau pathology toward ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation and reactive oxygen species. Advanced glycation end products further stabilize pathological tau species, creating a feed-forward loop in which oxidative stress, metal imbalance and protein misfolding reinforce one another. These mechanisms position tau as a node where metabolic stress and proteostatic failure converge, rather than a standalone culprit.

Perhaps the most conceptually ambitious section of the review extends tau pathology beyond neuronal boundaries. Pathological tau does not stay confined to the neurons that produce it. The authors describe how soluble tau species spread through tunneling nanotubes, extracellular vesicles and heparan sulfate proteoglycan-mediated uptake, seeding aggregation in recipient cells and propagating along anatomically connected networks, a pattern that resting-state functional MRI studies have begun to visualize in living patients. The low-density lipoprotein receptor-related protein 1 emerges as a key mediator of tau uptake and clearance, offering a potential point of therapeutic intervention. This network-level spread helps explain why tau burden follows predictable, stage-specific routes through the entorhinal cortex, hippocampus and association cortices rather than appearing randomly.

The review then situates tau within the broader ecosystem of Alzheimer’s disease, where it synergizes with amyloid-beta deposition to ignite neuroinflammation. Activated microglia and astrocytes release inflammatory mediators that both promote tau phosphorylation and impair its clearance. The blood-brain barrier, whose breakdown is increasingly recognized as an early event in the disease, permits peripheral immune molecules and plasma proteins to infiltrate the brain, further amplifying the inflammatory cascade. Strikingly, the authors extend this systems view to the gut-brain axis, citing evidence that gut dysbiosis and lipopolysaccharide-driven inflammation can modulate tau pathology through circulating immune signals. In this framework, tau phosphorylation behaves like a barometer of whole-body physiological state rather than an isolated intracellular defect.

On the translational front, the review surveys a new generation of biofluid biomarkers that are transforming how tau pathology is detected and tracked. Cerebrospinal fluid measures of phosphorylated tau have long served as diagnostic anchors, but plasma assays based on single-molecule array technology now achieve comparable diagnostic performance, opening the door to population-scale screening. Brain-derived tau, identified through immunoprecipitation-mass spectrometry, offers improved specificity for brain-derived over peripheral tau, while assays targeting the microtubule-binding repeat region may distinguish Alzheimer’s disease from other tauopathies, including chronic traumatic encephalopathy. The authors also point to emerging technologies such as organic electrochemical transistors that could enable point-of-care tau testing, potentially pairing fluid biomarkers with PET-based standardized uptake value ratios and resting-state functional MRI to stage disease with unprecedented resolution.

Therapeutically, the review maps a pipeline that extends well beyond the first generation of anti-tau antibodies. Monoclonal antibodies targeting specific phospho-epitopes are progressing through clinical trials, while antisense oligonucleotides aim to reduce tau production at the source. Small-molecule kinase inhibitors continue to be refined with attention to isoform selectivity. The most conceptually novel entry is a class of molecules the authors describe as dephosphorylation-targeting chimeras, or DEPTACs, which recruit phosphatases to phosphorylated tau in a manner analogous to the phosphorylation-targeting chimeras that recruit kinases. Related strategies include tauopathy-homing nanoassemblies designed to deliver payloads selectively to tau-bearing tissue. The review is careful to note that many of these modalities remain in early clinical investigation, and that target engagement, dosing windows and patient selection remain unresolved challenges.

The strategic implication of the review is that Alzheimer’s disease drug development may need to abandon the search for a single decisive target in favor of precision approaches aimed at the tau interactome. Because tau phosphorylation sits at the intersection of kinase signaling, proteostasis, nuclear integrity, metal metabolism, neuroinflammation and barrier function, interventions will likely need to be matched to the dominant pathogenic mechanisms operating in each patient, guided by fluid and imaging biomarkers that can stage both molecular pathology and network dysfunction. The authors frame their integrated model as a roadmap for such stratified trials, in which biomarker-defined subgroups receive mechanism-matched therapies.

For a field scarred by repeated late-stage failures, the reframing offered by this review is both sobering and energizing. It acknowledges that amyloid-centric therapies, including the recently approved antibody treatments, address only one strand of a tangled web, and that tau, with its stronger correlation to cognitive deterioration and synaptic dysfunction, offers a more direct line to the symptoms that matter to patients. Whether the multi-scale network view of tau phosphorylation can be converted into therapies that genuinely alter the course of Alzheimer’s disease will depend on the clinical performance of the biomarker and therapeutic platforms now moving through the pipeline, but the conceptual groundwork for that effort has, with this synthesis, been laid out in unusually complete detail.

Subject of Research: Tau phosphorylation mechanisms, network spread and therapeutic targeting in Alzheimer's disease

Article Title: Tau phosphorylation in Alzheimer’s disease: emerging mechanisms, network interactions, and therapeutic implications

Article References: Li, X., Zhang, L., Zhao, L., Qin, L., Bai, Q., Zeng, C., Gao, Z., Ni, J., Zeng, G., Saidova, A., Qing, H., & Li, H. (2026). Tau phosphorylation in Alzheimer’s disease: emerging mechanisms, network interactions, and therapeutic implications. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08889-2

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08889-2

Keywords: Alzheimer's disease, tau phosphorylation, neurofibrillary tangles, kinase-phosphatase equilibrium, post-translational modifications, neuroinflammation, blood-brain barrier, gut-brain axis, biomarkers, DEPTACs, antisense oligonucleotides, precision medicine

The core problem the authors identify is phenotypic heterogeneity. Sporadic Alzheimer’s disease accounts for roughly 90 percent of cases and is diagnosed clinically using cognitive testing, supported by amyloid and tau biomarkers in cerebrospinal fluid, blood plasma and PET imaging. But on the neuropathological level, the disease is far more complex than a simple case-versus-control division suggests. Amyloid plaques of extracellular beta-amyloid and intracellular neurofibrillary tangles of hyperphosphorylated tau are the hallmark lesions, yet comorbid pathology is the norm rather than the exception in the aging brain. Cerebral amyloid angiopathy, alpha-synuclein Lewy bodies, TDP-43 inclusions and granulovacuolar degeneration bodies frequently co-occur with hallmark Alzheimer lesions, sometimes at striking frequencies: TDP-43 inclusions can be found in up to 57 percent of Alzheimer’s patients and Lewy bodies in over 60 percent.

This complexity has direct consequences for genetic research. Twin studies estimate the heritability of sporadic Alzheimer’s disease at around 60 to 80 percent, and SNP-based heritability estimates rise from roughly 0.25 to 0.34 in clinical cohorts to 0.36 to 0.59 when autopsy or biomarker confirmation is used. More than 75 risk loci have now been associated with Alzheimer’s disease through GWAS, implicating pathways ranging from APP and tau processing to endocytosis, lipid metabolism and innate immunity. Yet clinical misclassification introduces type I and type II errors into large-scale studies, and some discovered signals may reflect co-pathologies or misdiagnosed subgroups rather than pure Alzheimer’s pathogenesis. The authors argue that smaller, deeply phenotyped cohorts can outperform ever-larger clinical samples because phenotypic accuracy is what limits statistical power, not sample size alone.

The review traces how this shift has already paid off for the hallmark lesions. Studies on the Religious Orders Study and Rush Memory and Aging Project (ROSMAP) cohorts, which follow cognitively normal individuals with longitudinal evaluation and brain donation, linked a CR1 intronic variant to increased neuritic plaque burden. Later work testing 83 risk variants from the largest clinical Alzheimer’s GWAS in a cohort of over 4,000 individuals found that BIN1, CR1 and COX7 variants increased neurofibrillary tangle burden while MME decreased it, and that BIN1, APH1B and FERMT2 variants raised neuritic plaque risk while MME, EED/PICALM and RBCK1 were protective. A genome-wide significant association between APOE and tangle pathology was repeatedly replicated, and an intronic PTPRD signal emerged in larger ROSMAP GWAS and was independently replicated.

Larger multicenter efforts extended these findings. The Alzheimer’s Disease Genetics Consortium performed GWAS of neuropathological phenotypes in nearly 5,000 individuals, confirming genome-wide significant APOE associations with all investigated lesions and identifying protective signals for GALNT7, ABCG1 and IER5I with neuritic plaques. A study of more than 7,000 autopsied participants from ROSMAP, NACC and ACT cohorts found APOE significantly associated with amyloid score, Braak stage and CERAD neuritic plaque score, plus a genome-wide significant BIN1 effect on higher Braak stages, with ABCA7, PTK2B, CR1, SNX1, FERMT2 and CELF/SPI1 raising plaque burden and PICALM, INPP5D, ZCWPW1 and SORL1 lowering it. Sex-stratified analyses added nuance, revealing a male-specific protective signal near TSPAN13 for tangle presence, though the authors caution that reduced statistical power in stratified analyses means such findings require independent replication.

Perhaps the most striking example of the approach’s value comes from primary age-related tauopathy, or PART, a condition in which tau lesions indistinguishable from Alzheimer’s occur without amyloid plaques and with limited cognitive consequences. A GWAS confined to neuropathologically confirmed PART cases uncovered a genome-wide significant locus on chromosome 4, with functional validation pointing to JADE1 as the plausible risk gene for tau pathology. Notably, the effect alleles in this locus were independent of earlier suggestive signals, illustrating how restricting cohorts to precisely defined pathological entities can reveal biology that overlapping, heterogeneously composed cohorts dilute or obscure.

Co-pathologies show equally illuminating genetic patterns. For cerebral amyloid angiopathy, found in up to 90 percent of Alzheimer’s cases, the APOE epsilon4 allele is specifically linked to capillary-involving Type I disease, while epsilon2 is more frequent in Type II. Beyond APOE, CR1 and UNC5C were implicated in hypothesis-driven studies, and a GWAS in over 800 individuals identified the long noncoding RNA locus LINC-PINT, associated with decreased CAA burden in APOE epsilon4-negative individuals and supported by in vitro evidence of neuroprotection. A protective APOC2 polymorphism in a large postmortem GWAS was later shown by colocalization to reflect reduced APOE expression in brain microglia, demonstrating how post-GWAS fine-mapping can redirect interpretation from the nearest gene to the true molecular driver.

For TDP-43 pathology and the related entity LATE (limbic-predominant age-related TDP-43 encephalopathy), much of the genetic insight has come from frontotemporal lobar degeneration research, where neuropathology-centered GWAS revealed TMEM106B, DPP6, UNC13A, HLA-DQA2 and TNIP1 as risk factors, with distinct loci emerging for specific FTLD-TDP subtypes. In the Alzheimer’s context, APOE epsilon4 allele count correlates with TDP-43 burden, and TMEM106B was confirmed as associated with LATE neuropathological change, alongside suggestive signals for GRN, SORL1 and TPCN1. Both TMEM106B, a lysosomal transmembrane protein whose C-terminal domain can form amyloid fibrils, and GRN, encoding the lysosomal growth factor progranulin, implicate lysosomal dysfunction as a shared mechanism spanning Alzheimer’s and TDP-43 proteinopathies. For Lewy body pathology, APOE and BIN1 are firmly established Alzheimer’s risk genes whose links to alpha-synuclein aggregates remain contested; one stratified GWAS concluded they raise Alzheimer’s risk regardless of Lewy body status, while BLMH and ZNF365 signals emerged for Lewy body presence in Alzheimer’s-negative individuals. Granulovacuolar degeneration, an underexplored lesion strongly tied to tau pathology, endocytosis, autophagy and necroptosis, showed APOE and APH1B associations that network modeling suggested are largely indirect, mediated through amyloid and tangle pathology.

The authors are candid about the caveats. Neuropathological cohorts are necessarily small because donated brain tissue is limited, forcing reliance on multi-center compilations that introduce inter-observer variability, differing staining protocols and harmonization challenges, though initiatives like BrainNet Europe have shown that immunohistochemistry with standardized antibodies and dichotomous diagnostic approaches yield the most robust results. Overlapping study populations across published GWAS also limit independence of findings, underscoring the need for new, standardized cohorts. Moreover, GWAS lead variants are often not the causal variants, and the nearest protein-coding gene is not necessarily the affected gene, since most hits sit in noncoding regulatory regions; gene prioritization and functional validation remain essential before mechanistic claims can be made.

Even so, the message of the review is unambiguous: bigger is not always better. Combining genetic data with detailed neuropathology enables refinement of clinical GWAS signals, discovery of variants tied to the burden of specific lesions rather than a diagnostic label, network analyses that position APOE’s effects on tau as largely indirect through amyloid and vascular pathology, and identification of overlapping genetic risk across disease boundaries. As the first disease-modifying Alzheimer’s therapies arrive, understanding which genes drive which lesions, and how co-pathologies shape disease trajectory, could enable the patient stratification that clinical trials increasingly demand, and point toward treatments addressing the full neuropathological spectrum rather than a single pathological feature.

Subject of Research: Neuropathology-centered genome-wide association studies of Alzheimer's disease and overlapping co-pathologies

Article Title: A new era of genome-wide association studies in the field of Alzheimer’s disease and overlapping co-pathologies: lessons learned from a neuropathology-centered approach

Article References: A new era of genome-wide association studies in the field of Alzheimer’s disease and overlapping co-pathologies: lessons learned from a neuropathology-centered approach. (n.d.). https://doi.org/10.1007/s00401-026-03085-4

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03085-4

Keywords: Alzheimer's disease, genome-wide association studies, neuropathology, amyloid plaques, neurofibrillary tangles, cerebral amyloid angiopathy, TDP-43, Lewy bodies, APOE, TMEM106B, co-pathologies, LATE

A new study published in the Journal of Advanced Research offers a strikingly different approach to attacking tau at its upstream source. Rather than blocking the activity of one of tau’s key dysregulating kinases, the research team designed a small molecule that eliminates the kinase protein itself. The target is death-associated protein kinase 1, or DAPK1, an enzyme that has accumulated an impressive pathogenic dossier in Alzheimer’s research. DAPK1 activates MARK1/2 to trigger abnormal tau phosphorylation, directly phosphorylates tau at disease-relevant residues, and through phosphorylation of SENP1 promotes tau SUMOylation, exacerbating tau pathology and cognitive dysfunction. Genetic knockdown and pharmacological inhibition of DAPK1 have both been shown to reduce tau phosphorylation and mitigate neurodegeneration in cell and animal models. Yet traditional small-molecule kinase inhibitors suffer from well-known drawbacks: short-lived efficacy, compensatory signaling from parallel pathways, and substantial off-target liability.

To overcome these limitations, the team turned to targeted protein degradation, a next-generation pharmacological strategy that hijacks the cell’s own proteostasis machinery. Their specific platform is hydrophobic tagging, or HyT, in which a bifunctional molecule couples a ligand that binds the protein of interest to a bulky hydrophobic moiety, typically adamantane, that mimics the exposed greasy surfaces of misfolded proteins. The cell’s quality-control machinery is fooled into ubiquitinating the tagged protein and destroying it via the ubiquitin-proteasome system. Adamantane-based hydrophobic tags carry distinct advantages over the better-known PROTAC degraders: simpler molecular design, lower molecular weight, favorable ADME characteristics, and high degradation efficiency. The approach has already been used to degrade tau, TDP-43, and mutant huntingtin, but it had never been applied to DAPK1.

From a library of candidate degraders built by conjugating a previously characterized DAPK1-binding ligand to adamantane- or fluorene-based hydrophobic tags through alkylamine linkers of varying length, one compound emerged as the clear leader. Named CJ1, the molecule reduced DAPK1 protein levels in mouse primary cortical neurons to roughly half of control levels at a screening concentration of 1 micromolar, outperforming all other compounds in the series. Molecular docking suggested that CJ1’s DAPK1-binding moiety occupies a distinct hydrophobic pocket on the kinase surface, with favorable electrostatic complementarity at the binding interface. Critically, cytotoxicity testing showed that CJ1 did not compromise the viability of primary neurons even at concentrations up to 20 micromolar, providing a wide margin between functional activity and cellular harm.

The mechanistic characterization of CJ1 was rigorous. In primary cortical neurons, the compound degraded DAPK1 in a dose-dependent fashion, with a half-maximal degradation concentration of approximately 0.18 micromolar, and a time course showing detectable degradation beginning four hours after treatment and sustained suppression lasting up to 48 hours. Quantitative PCR confirmed that DAPK1 mRNA levels were unchanged, indicating a posttranslational mechanism. When cells were pretreated with the proteasome inhibitor MG-132, CJ1-induced degradation was abolished, and ubiquitination assays demonstrated markedly increased polyubiquitinated DAPK1 in the presence of the compound. Together, these experiments established that CJ1 marks DAPK1 for ubiquitin-dependent proteasomal destruction, precisely the event-driven behavior expected of a hydrophobic tagging degrader.

With the mechanism confirmed, the investigators asked whether eliminating DAPK1 would tame tau. In primary cortical neurons, SH-SY5Y neuroblastoma cells, and SH-SY5Y cells expressing the P301L mutant human tau, CJ1 treatment reduced levels of tau phosphorylated at threonine 231, serine 262, and serine 396, along with total tau. These phosphorylation sites are deeply meaningful in Alzheimer’s biology: phosphorylation at Ser262 within the microtubule-binding repeat domain critically weakens tau’s grip on microtubules, Thr231 primes tau for further phosphorylation by GSK3beta and contributes to microtubule destabilization, and the Ser396/404 epitope marks advanced pathological tau. Several control experiments reinforced the specificity of the effect. CJ1 did not alter the levels of the major tau kinases GSK3beta and CDK5, the phosphatase PP2A, or the related kinase DAPK3. In DAPK1 knockout neurons, CJ1 lost its ability to reduce tau or phospho-tau, and a control compound lacking the DAPK1-binding moiety was inert. Overexpressing DAPK1 in cells also rescued the phenotype, strongly arguing that CJ1 acts specifically through DAPK1 degradation rather than through incidental off-target effects.

The in vivo results were the most consequential. A central hurdle for any Alzheimer’s therapeutic is crossing the blood-brain barrier, and liquid chromatography-mass spectrometry confirmed that intact CJ1 was detectable in mouse brain after systemic administration. In a tauopathy model created by injecting an adeno-associated virus carrying human P301L tau into the hippocampal CA3 region, DAPK1 was upregulated and CJ1 treatment lowered it in a dose-dependent manner, with 10 milligrams per kilogram nearly restoring baseline levels. CJ1 reduced human tau accumulation and phosphorylation at Thr231 and the AT8 epitope in the hippocampus. In aged hTau transgenic mice, which express all six human tau isoforms and develop genuine neurofibrillary tangles, five weeks of CJ1 treatment significantly reduced tangle burden in the cortex and lowered total tau and phospho-tau at multiple AD-relevant sites in both sarkosyl-soluble and, importantly, sarkosyl-insoluble fractions, the biochemical signature of aggregated, pathological tau.

Pathology translated into preserved brain structure and function. CJ1-treated tauopathy mice retained more NeuN-positive neurons, showed restored MAP2 immunoreactivity indicating healthier dendrites, and displayed dose-dependent recovery of dendritic spine density on Golgi-Cox staining. Neuroinflammation also receded: astrocytic activation marked by GFAP and microglial activation marked by Iba1 were both suppressed, pro-inflammatory iNOS decreased, and anti-inflammatory Arg-1 increased. Functionally, in the Morris water maze, CJ1-treated mice learned the platform location faster, spent more time in the target quadrant during the probe trial, and crossed the former platform location more often, with all groups swimming at comparable speeds, ruling out motor confounds. Notably, only the higher dose produced cognitive improvement, suggesting that partial biochemical correction of tau pathology is insufficient and that robust suppression is required for behavioral benefit.

Safety data were encouraging. CJ1 showed negligible hemolysis at concentrations up to 800 micrograms per milliliter, serum creatinine, ALT, and AST remained within normal ranges, and histological examination of the heart, liver, lung, and kidney revealed no treatment-related abnormalities. The authors are candid about limitations: the behavioral findings derive from an acute, region-specific model; the selectivity screen covered only a small panel of proteins; and the detailed brain distribution of CJ1 remains unmapped, as do potential differential effects on 3R versus 4R tau isoforms. Nonetheless, the study establishes CJ1 as a first-in-class DAPK1 degrader and provides a compelling proof of concept that hydrophobic tagging can eliminate an upstream driver of tau pathology inside cells, something neither conventional kinase inhibitors, which transiently block catalytic activity, nor tau immunotherapies, which target extracellular aggregates, can accomplish. By abolishing all of DAPK1’s functional domains and scaffolding roles in a catalytic, substoichiometric manner, this degrader strategy offers a mechanistically distinct and potentially more durable route to slowing the neurodegeneration that lies at the heart of Alzheimer’s disease.

Subject of Research: A hydrophobic tagging degrader that selectively eliminates DAPK1 to attenuate tau pathology in Alzheimer's disease

Article Title: Selective degradation of DAPK1 via a novel hydrophobic tagging attenuates tau pathology in Alzheimer’s disease

Article References: Li, R., Wu, X., Yao, J., Chen, J., Shui, X., Zheng, X., Tian, W., Wang, L., Zhou, Y., Zhang, T., Chen, D., Liu, Y., & Lee, T. H. (2026). Selective degradation of DAPK1 via a novel hydrophobic tagging attenuates tau pathology in Alzheimer’s disease. Journal of Advanced Research, 87, 1027-1043. https://doi.org/10.1016/j.jare.2025.12.037

Image Credits: AI Generated

DOI: 10.1016/j.jare.2025.12.037

Keywords: Alzheimer's disease, DAPK1, tau pathology, hydrophobic tagging, targeted protein degradation, neurofibrillary tangles, proteasome, tau phosphorylation, blood-brain barrier, neurodegeneration, drug discovery, tauopathy

The research focuses on tau, one of the two hallmark proteins of Alzheimer’s pathology. Tau accumulates inside neurons in a remarkably stereotyped sequence, first appearing in the transentorhinal region, then spreading through the hippocampal formation and association cortices in a progression that pathologists have catalogued for decades as Braak stages. Neurofibrillary tangles of tau are closely correlated with neuronal loss and cognitive decline, which is why imaging tau in living brains has become one of the most actively pursued goals in dementia research.

What has remained less clear is how this cortical tau burden relates to the well-documented degeneration of subcortical structures such as the thalamus, basal ganglia, and brainstem nuclei. These deep gray matter regions are not passive bystanders in Alzheimer’s disease. Postmortem studies repeatedly find tau pathology and neuronal loss in structures like the locus coeruleus and the nucleus basalis, which send widespread projections throughout the cortex and are among the earliest sites of pathological change. Yet the functional relationship between subcortical damage and cortical tau spread has been difficult to quantify in living patients.

The new work addresses that gap by treating the brain as a single integrated dynamical system rather than a collection of independent regions. Using resting-state functional imaging, the team derived measures of global brain activity, capturing how fluctuations in neural signaling are coordinated across the entire organ. Instead of examining the cortex and the subcortex in isolation, the analysis explicitly tested whether the strength of global activity coupling changes systematically across Braak-defined regions as Alzheimer’s progresses from preclinical stages through mild cognitive impairment.

The results reveal a clear progressive pattern. In individuals without measurable tau pathology, the functional dialogue between subcortical structures and the cortex follows a relatively stable organization. But as tau begins to accumulate in the transentorhinal and limbic regions, defined by the early Braak stages, the relationship shifts. Degeneration in subcortical gray matter becomes increasingly tied to global activity measures, and this linkage intensifies as tau advances into neocortical association areas in later preclinical and early symptomatic stages.

Crucially, the progression is spatially organized. The researchers found that the strength of the subcortical-cortical coupling tracked the sequential involvement of Braak regions, meaning that the deepest subcortical degeneration was most strongly associated with tau burden in precisely those cortical areas known to be affected at each stage. This staged correspondence argues against the idea that subcortical atrophy is merely a nonspecific consequence of overall disease severity. Instead, it suggests a mechanistic relationship in which damage to deep nuclei that broadly innervate the cortex may influence, or at least mirror, the regional vulnerability of the cortex to tau.

One plausible biological interpretation involves the cholinergic and noradrenergic systems. The nucleus basalis of Meynert, located in the basal forebrain, supplies acetylcholine to the entire cortical mantle, while the locus coeruleus in the brainstem provides norepinephrine with an even wider reach. Both systems are compromised early in Alzheimer’s disease, and both play roles in regulating neural activity, arousal, and the cellular stress responses that govern tau phosphorylation. A failing subcortical modulatory system could plausibly alter cortical network dynamics in ways that create conditions favorable to tau aggregation and spread along existing anatomical connections.

The study’s use of global brain activity as an integrative marker also carries methodological significance. Standard analyses often average activity within predefined regions of interest, which can obscure distributed phenomena. By characterizing whole-brain signal properties, the researchers captured a systems-level signature of disease progression that single-region measures would miss. This approach aligns with a growing recognition, driven by large-scale neuroimaging consortia, that Alzheimer’s disease is fundamentally a network disorder, with pathology propagating along functional and structural connections rather than emerging randomly across the brain.

The clinical implications are potentially substantial. If subcortical degeneration and global activity disruption can be measured reliably in the preclinical window, they may serve as early indicators of impending cortical tau spread, complementing existing PET-based tau imaging and cerebrospinal fluid biomarkers. Because subcortical structures can be quantified with widely available MRI sequences, a systems-level marker derived from standard scans could extend the reach of early detection to clinical settings where advanced PET imaging is not accessible, and could provide sensitive outcome measures for trials of anti-tau therapies targeting the earliest disease stages.

The findings also reframe the conceptual geography of Alzheimer’s disease. Rather than a cortical illness with subcortical complications, the condition increasingly appears as a whole-brain process in which deep nuclei and the cortex deteriorate in a coordinated, staged fashion. Understanding the direction of causality, whether subcortical dysfunction actively promotes cortical tau spread or both reflect a shared upstream trigger, remains the central open question. Longitudinal studies combining serial tau PET, structural imaging of subcortical nuclei, and global activity mapping in the same individuals will be essential to answer it. For now, the study adds a compelling piece of evidence that the brain operates as an integrated system in health and in disease, and that the seeds of cortical destruction in Alzheimer’s may be nourished from below.

Subject of Research: Progressive coupling of subcortical degeneration and cortical tau spread across Braak regions in early Alzheimer's disease measured by global brain activity

Article Title: Global brain activity links subcortical degeneration to cortical tau progressively across Braak regions over early Alzheimer’s disease stages

Article References: Mao, Y., Pan, B., & Liu, X. (2026). Global brain activity links subcortical degeneration to cortical tau progressively across Braak regions over early Alzheimer’s disease stages. Nature Communications. https://doi.org/10.1038/s41467-026-77748-x

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77748-x

Keywords: Alzheimer's disease, tau pathology, Braak stages, subcortical degeneration, global brain activity, neuroimaging, cortex, biomarkers, neurodegeneration, Nature Communications, Global, brain

The research, conducted by a team at Shandong Second Medical University in Weifang, China, and published in BMC Medical Imaging, analyzed longitudinal tau-PET imaging data from participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Rather than treating tau as a single, uniform burden across the brain, the investigators asked a more granular question: which regions of tau accumulation carry the strongest warning about conversion from mild cognitive impairment (MCI) to full Alzheimer’s disease?

Tau is one of the two hallmark proteins of Alzheimer’s disease, the other being beta-amyloid. While amyloid plaques can accumulate for decades without obvious cognitive decline, tau—especially when it forms neurofibrillary tangles inside neurons—tracks much more closely with the actual death of brain cells and the erosion of memory and thinking abilities. Tau PET imaging, which uses radioactive tracers that bind to the pathological protein, allows researchers to visualize and quantify this burden in living patients rather than relying on autopsy data.

To identify the key regions, the team applied three complementary analytical methods to the imaging data: penalized generalized estimating equations (PGEE), which use a smoothly clipped absolute deviation penalty to screen variables while accounting for repeated measures in the same person; mixed-effects gradient boosting (MEGB); and mixed-effects random forest (MERF), two machine learning approaches that model longitudinal trajectories while capturing nonlinear relationships and individual variability. Only regions jointly identified by all three methods were carried forward, a deliberately conservative strategy designed to reduce the risk of false discoveries.

Six brain regions passed this triple filter: the entorhinal cortex, the amygdala, the inferior parietal cortex, the middle temporal gyrus, the parahippocampal gyrus, and the ventral posterior cingulate cortex. Many of these are familiar territory in Alzheimer’s research. The entorhinal cortex, a gateway structure connecting the hippocampus to the rest of the cortex, is typically the earliest site of tau accumulation and is central to memory function. The parahippocampal gyrus and amygdala, both parts of the medial temporal lobe’s memory circuitry, follow closely behind in the disease’s stereotypical spread pattern.

The researchers then constructed a multilevel joint model—a sophisticated statistical framework that simultaneously analyzes the longitudinal trajectory of tau deposition and the time-to-event process of conversion from MCI to Alzheimer’s disease. Joint models are powerful because they link the two processes, allowing the evolving tau measurements over repeated scans to directly inform the estimated risk of disease progression at each moment in time. This is a step beyond simpler approaches that rely on a single baseline scan, which can miss the dynamics of how tau evolves in individual patients.

The results revealed a striking hierarchy among the six regions. The entorhinal cortex showed the strongest association with progression risk, with a hazard ratio of 3.763 (95% confidence interval: 2.237–6.801), meaning that higher tau burden in this region roughly quadrupled the risk of converting to Alzheimer’s disease. The amygdala followed closely at a hazard ratio of 3.732 (95% CI: 2.326–6.164), and the inferior parietal cortex at 3.511 (95% CI: 2.109–6.013). The middle temporal gyrus (hazard ratio 2.770, 95% CI: 1.972–3.955) and the parahippocampal gyrus (hazard ratio 2.522, 95% CI: 1.833–3.529) also showed significant associations.

Notably, one region did not make the cut of meaningful predictors. The ventral posterior cingulate cortex, despite being jointly selected by all three screening methods, showed a hazard ratio of 1.354 with a confidence interval spanning 0.858 to 2.164—an interval that includes 1.0, indicating the association with progression risk was not statistically significant. This kind of heterogeneity across regions, the authors emphasize, is exactly why the multilevel joint modeling approach matters: tau in different brain areas is not equally informative about a patient’s future.

Perhaps the most clinically consequential finding concerns the timing of tau accumulation. When the researchers examined whether the rate of tau buildup—the trajectory or slope over repeated scans—or the current level of tau burden was the better predictor of progression, the answer was clear: current tau burden, rather than its accumulation rate, emerged as the dominant factor associated with the risk of conversion. In practical terms, where a patient’s tau levels stand right now matters more for predicting near-term progression than how fast those levels have been climbing.

This distinction has implications for how tau PET data might be used in clinical trials and, eventually, in clinical practice. Anti-amyloid therapies have recently received regulatory approval, but the field has long recognized that tau pathology is the stronger correlate of neuronal injury and cognitive decline. If the amount of tau in specific regions at a given visit is the most informative signal, then monitoring those regions could help identify MCI patients at highest risk who might benefit most from early intervention—and could serve as sensitive outcome measures in trials of tau-targeting therapies.

The study’s data came from the ADNI database, a widely used public resource that has followed hundreds of older adults with serial imaging, fluid biomarkers, and cognitive assessments. All participants provided written informed consent, and the analysis used de-identified data under the ADNI data use agreement. Using longitudinal tau-PET data—repeated scans from the same individuals over time—allowed the team to model within-person trajectories as well as between-person differences, a distinction captured by the mixed-effects and multilevel structure of their models.

The methodological pipeline itself represents a growing trend in Alzheimer’s research: combining classical biostatistics with machine learning to handle the high dimensionality of brain imaging. Tau PET scans yield standardized uptake value ratios (SUVRs) for dozens of distinct brain regions, and identifying which of these carry prognostic weight requires variable selection methods robust to correlation among regions and repeated measurements. The triangulation across PGEE, MEGB, and MERF gives the findings a level of robustness that any single method alone would not provide.

The work was supported by the National Natural Science Foundation of China, the Natural Science Foundation of Shandong Province, and regional science and technology programs, and it is published open access. The authors, led by Yanxia Wang, Xinyu Yang, Yonghua Ma, and Aimin Wang as co-first authors, with Suzhen Wang and Fuyan Shi as corresponding authors, note that the study is citable under a permanent DOI while the final version of record is being completed.

For the field, the study adds a quantitative layer to a picture that has been forming for years: tau spreads through the brain along predictable pathways, and the specific regions it reaches—and how much of it settles there—encode information about how quickly a person will decline. By showing that the entorhinal cortex, amygdala, inferior parietal cortex, middle temporal gyrus, and parahippocampal gyrus each independently raise the risk of conversion from MCI to Alzheimer’s disease, and by quantifying that risk with region-specific hazard ratios, the study moves the field closer to a personalized, imaging-based prognostic tool.

That tool remains on the horizon rather than in the clinic. The findings are based on 126 participants, and hazard ratios from observational models describe associations, not certainty about any individual patient’s trajectory. Validation in independent cohorts, and integration with other biomarkers such as amyloid status and fluid markers of neurodegeneration, will be needed before tau PET in these five regions can guide individual clinical decisions. But as the search for effective Alzheimer’s treatments intensifies, knowing exactly where to look—and what level of tau in those places means for the road ahead—gives researchers and clinicians a sharper map of the disease’s most decisive early chapter.

Tau has long been associated with Alzheimer’s disease because abnormal forms of the protein can be detected in cerebrospinal fluid and blood before symptoms become apparent. In affected brain tissue, tau accumulates inside neurons in structures known as neurofibrillary tangles. Under normal conditions, tau binds to and helps stabilize microtubules, the intracellular tracks that support the transport of materials through nerve cells. In disease, however, tau can become excessively phosphorylated, meaning that phosphate groups are attached to numerous sites along the protein. This modification alters tau’s behavior, location and ability to interact with other cellular components.

The Stanford-led study, published online in Neuron on Aug. 6, suggests that hyperphosphorylated tau can cause damage even without forming tangles. Researchers found that particular phosphorylation patterns allow tau to move into mitochondria, the organelles responsible for producing most of a cell’s adenosine triphosphate, or ATP. ATP supplies the energy required for neuronal communication, transport and maintenance. Because neurons have exceptionally high energy demands, mitochondrial dysfunction can rapidly compromise their structure and function.

Inside mitochondria, the modified tau molecules interact with NDUFS3, a component of complex I, the first major enzyme assembly in the mitochondrial electron-transport chain. Under normal conditions, electrons pass through a series of protein complexes embedded in the inner mitochondrial membrane. The energy released during this process pumps protons across the membrane, creating an electrochemical gradient that powers ATP synthase. Tau’s binding to NDUFS3 appears to distort the complex and interfere with the normal direction of electron flow.

The result is a process called reverse electron transport. Instead of moving forward through the respiratory chain, electrons flow backward under conditions that favor the reaction, producing unusually large quantities of reactive oxygen species. These chemically reactive molecules can damage proteins, lipids and nucleic acids, while also activating inflammatory signaling pathways. The researchers found evidence of reverse electron transport in fruit flies and mice with tau-related disease, as well as in human brain tissue affected by tauopathy. Healthy neurons showed little or no evidence of the process.

The findings emerged from experiments involving multiple disease models, including animals carrying tau mutations associated with human tauopathies and laboratory-generated human neurons derived from patient cells. The team also studied neurons with a gene duplication linked to an increased risk of early Alzheimer’s disease. Across these systems, mitochondrial stress was closely associated with phosphorylated tau. Removing or reducing tau genetically prevented the abnormal electron flow, while an experimental compound called CPT blocked the interaction between hyperphosphorylated tau and NDUFS3 without stopping normal electron transport.

Animal experiments provided additional evidence that this interaction contributes directly to neurological decline. Fruit flies lacking tau were protected from the severe nervous-system damage and shortened lifespan normally caused by prolonged heat stress. CPT treatment produced similar protection in tau-producing flies and extended their survival. In mice, tau reduction or CPT treatment helped preserve cognition under stressful conditions. In mice with severe tauopathy and cognitive impairment, longer-term CPT administration reduced reverse electron transport in brain mitochondria and improved performance across several behavioral tests.

The treatment also appeared to reduce biological signs of neurodegeneration. CPT-treated animals showed less nerve-cell inflammation and were protected against changes including reduced cortical thickness and loss of total brain volume. In human neurons generated from induced pluripotent stem cells carrying disease-associated tau mutations, CPT prevented several stress-related cellular abnormalities. The convergence of results from animal models, patient-derived neurons and human brain tissue suggests that the mechanism may operate in the human nervous system, although it does not yet establish that CPT is safe or effective as a treatment for patients.

The researchers describe the process as a self-reinforcing loop. Reverse electron transport generates reactive oxygen species, which can promote still more tau phosphorylation. Newly modified tau molecules may then enter mitochondria, bind additional NDUFS3 and further impair respiration. This cycle could help explain how an initially limited mitochondrial disturbance develops into widespread neuronal dysfunction. It also raises the possibility that blocking the tau–NDUFS3 interaction or preventing reverse electron transport could interrupt disease progression without eliminating tau’s normal functions.

The work broadens the range of tau-related mechanisms under investigation in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, frontotemporal dementia and progressive supranuclear palsy. It may also have relevance to other conditions involving phosphorylated tau and mitochondrial stress, including stroke, traumatic brain injury and some brain tumors. CPT remains an experimental compound, and substantial research will be required before clinical trials can be considered. Bingwei Lu, the study’s senior author, is a co-founder and advisory-board member of Cerapeut Inc., which is developing CPT for neurodegenerative diseases. The study also involved researchers from the University of California, San Francisco, and was supported by grants from the U.S. National Institutes of Health.

Subject of Research: The role of hyperphosphorylated tau in mitochondrial dysfunction and tauopathies.

Article Title: Hyperphosphorylated Tau Disrupts Mitochondrial Energy Production Through Reverse Electron Transport

News Publication Date: Aug. 6

Web References: Stanford Medicine; Stanford School of Medicine; med.stanford.edu

References: Study published online in Neuron; National Institutes of Health grants R21AG083863, R01NS084412, R01AG089752, R37NS083417 and R01NS120219.

Keywords: Alzheimer’s disease, tau, tauopathies, mitochondria, reverse electron transport, NDUFS3, oxidative stress, neurodegeneration, CPT, mitochondrial dysfunction

The study was conducted on Wistar rats that were exposed to aluminium chloride, a substance known to induce neurotoxicity and facilitate the formation of amyloid plaques and neurofibrillary tangles. The researchers meticulously administered Ficus religiosa leaf extract to these rats and monitored the changes in their neurological health. The results were remarkable, revealing a significant reduction in the presence of neurotoxic aggregates, suggesting the extract’s impressive capability to reverse the effects of induced neurodegeneration.

Neurodegenerative diseases such as Alzheimer’s are characterized by a progressive decline in cognitive function, largely attributed to the accumulation of amyloid beta plaques and paired helical filaments in the brains of affected individuals. Such findings demonstrate the efficacy of herbal treatments that have been traditionally overlooked in contemporary medicine. By integrating ethnobotanical knowledge with modern scientific inquiry, the study provides compelling evidence that natural compounds have a pivotal role in cognitive preservation and restoration.

The phytochemical composition of Ficus religiosa is touted for its diverse bioactive compounds, including flavonoids, tannins, and phenolic acids. These compounds are believed to exert antioxidant effects that neutralize free radicals and combat oxidative stress—a known contributor to cognitive decline. It’s these protective features that researchers are increasingly focusing on to address the chronic inflammation and cellular damage that underlie neurodegenerative diseases.

In the experiment, the rats that received the leaf extract exhibited marked improvements in behavioral tests that measure cognitive function. Such behavioral assessments are critical in establishing the efficacy of therapeutic agents, offering insights into how treatments can mitigate stress-induced cognitive decline. The results advocate for further exploration into herbal pharmacology as it pertains to neurodegenerative diseases, setting a precedence for future studies focused on plant-based therapeutics.

The neuroprotective potential of Ficus religiosa can have significant implications for public health. As the elderly population continues to rise globally, so does the prevalence of Alzheimer’s and other neurodegenerative conditions, making this research exceptionally timely. By exploring the medicinal properties of plants that have culturally been used for generations, scientists are delving into a treasure trove of knowledge that could lead to effective interventions against age-related cognitive decline.

As the study progresses, the researchers emphasize the importance of understanding the molecular mechanisms behind the observed neuroprotective effects. It remains essential to identify which specific compounds within the Ficus religiosa extract contribute most significantly to its protective capabilities. This understanding could not only enhance the formulation of future treatments but also provide a framework for the synthesis of new drugs that mimic these beneficial phytochemicals.

Collaborations between conventional medicine and herbal practices are increasingly being recognized as a viable approach for treating complex diseases. Findings from such studies encourage a more integrative perspective towards therapy, wherein the complementary aspects of traditional and modern medicine can flourish together. As clinicians begin to appreciate the value of phytotherapy, patient care can become more holistic, addressing both the symptoms and underlying causes of neurodegenerative diseases.

Furthermore, the study calls for comprehensive clinical trials to assess safety and efficacy before the widespread use of Ficus religiosa in therapeutic contexts. Understanding the pharmacokinetics and potential side effects of herbal extracts is vital to ensure that natural remedies can be safely incorporated into treatment regimens. Rigorous scientific methodology will help bridge the gap between traditional knowledge and modern therapeutic practices, establishing a new paradigm in the fight against neurodegeneration.

The broader implications of this research extend beyond just one plant; it represents a growing movement towards identifying plant-based solutions to health crises affecting millions. With the continual discovery of new bioactive compounds from various plants, there is hope that more natural treatments for a wide range of ailments may soon be on the horizon. This study is an initial step towards quelching the mystery surrounding effective plant-based neurotherapeutics, further igniting interest in the synergy of nature and science.

In conclusion, as researchers continue to investigate the capabilities of Ficus religiosa and other medicinal plants, a new chapter in neuropharmacology may be unfolding. This study not only adds to our understanding of the sacred fig’s potential but also inspires ongoing research into the myriad of ways that nature can guide us toward healing. A greater appreciation for traditional knowledge, paired with modern scientific rigor, may offer the keys to unlocking future advancements in neurodegenerative disease treatment.

The findings from the research conducted by Massand and colleagues highlight a promising intersection between ancient wisdom and contemporary scientific investigation. As we stride confidently towards exploring the medical applications of botanicals, we may better understand how to preserve our cognitive health amidst the challenges posed by aging populations and degenerative diseases. The future holds promise, and the potential for Ficus religiosa as a therapeutic agent may just be the beginning of a widespread renaissance in the field of herbal medicine and its role in neurological health.

Subject of Research: Neuroprotective effects of Ficus religiosa leaf extract on neurodegeneration in Wistar rats.

Article Title: Ficus religiosa leaf extract mitigates the neurofibrillary tangles and amyloid plaques in aluminium chloride exposed Wistar rat brain.

Article References:

Massand, A., Rai, R., Rai, A.R. et al. Ficus religiosa leaf extract mitigates the neurofibrillary tangles and amyloid plaques in aluminium chloride exposed Wistar rat brain. 3 Biotech 16, 54 (2026). https://doi.org/10.1007/s13205-025-04647-1

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s13205-025-04647-1

Keywords: Neuroprotection, Ficus religiosa, Alzheimer’s disease, neurodegeneration, traditional medicine, phytochemistry, cognitive health.